drugset / Trial / NCT01937299
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy (TRAVATAN Z®).
Timeline
- Start
- 2013-10
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIMBRINZA | Unknown | 0.2 % | Other |
| Subject | SIMBRINZA | Unknown | 1 % | Other |
| Background | Travoprost | Other / unclassified | 0.004 % | Other |